XCancer

68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma

Description:

This is a prospective, single-center, single-arm, phase I/II study designed to evaluate (1) the safety, tolerability, and imaging characteristics of 68Ga-NYM207 (Phase A), and (2) the diagnostic performance of 68Ga-NYM207 in detecting hepatocellular carcinoma (HCC) (Phase B). This study will provide critical insights into the performance of 68Ga-NYM207 PET/CT as a non-invasive imaging tool for the detection of HCC.

Sponsor:

Peking Union Medical College Hospital

Phase:

Phase 1/2

Contacts:

Li Huo (CONTACT)

huoli@pumch.cn

+86 18612672038

Wenjia Zhu (CONTACT)

zhuwenjia_pumc@163.com

+86 18614080164

Government Study Link:

NCT07590336 - Click here to see study on

ClinicalTrials.gov

Inclusion
  • with a history of HCC, recurrence or metastasis during follow-up (based on histopathologic examination or typical appearance of imaging data including conventional imaging or 18F-FDG PET/CT scan);
  • Written informed consent provided for participation in the trial;
  • 1. ≥18 years of age and of either gender;
  • At least one of the following indications should be applied:
  • scheduled for surgical resection or biopsy of the liver mass within one month;
Exclusion
  • Any condition deemed by the investigator to interfere with study results or increase participant risk.
  • Severe claustrophobia;
  • 1. Pregnancy or lactation;
  • On treatment with anti-tumor drugs targeting GPC3;